Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

Trial Profile

Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs ALT 803 (Primary) ; ETBX 011 (Primary)
  • Indications Colon cancer; Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NantCell
  • Most Recent Events

    • 04 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 02 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top